Literature DB >> 14305352

IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY.

R R STRANG.   

Abstract

Entities:  

Keywords:  CLINICAL RESEARCH; DRUG THERAPY; IMIPRAMINE; PARKINSONISM; PLACEBOS

Mesh：

Substances：

Year:  1965        PMID： 14305352      PMCID： PMC1845500          DOI： 10.1136/bmj.2.5452.33

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

1.  Office treatment of depressive states with a new drug (imipramine).

Authors:  H STRAUSS
Journal:  N Y State J Med       Date:  1959-08-01

2.  IMIPRAMINE AND "DRINAMYL" IN DEPRESSIVE ILLNESS: A COMPARATIVE TRIAL.

Authors:  E H HARE; C MCCANCE; W O MCCORMICK
Journal:  Br Med J       Date:  1964-03-28

3.  The evaluation of imipramine in the treatment of Parkinson's disease.

Authors:  R O GILLHESPY; D M MUSTARD
Journal:  Br J Clin Pract       Date:  1963-04

4.  [Treatment of depressive states with an iminodibenzyl derivative (G 22355)].

Authors:  R KUHN
Journal:  Schweiz Med Wochenschr       Date:  1957-08-31

5.  Parkinson's syndrome, depression and imipramine. A preliminary report.

Authors:  A J MANDELL; C MARKHAM; W FOWLER
Journal:  Calif Med       Date:  1961-07

6.  Imipramine hydrochloride (Tofranil) in Parkinsonism. A preliminary report.

Authors:  J C DENMARK; J D DAVID; S G McCOMB
Journal:  Br J Clin Pract       Date:  1961-06

7.  A controlled trial of imipramine ("Tofranil") in the treatment of severe depressive states.

Authors:  L REES; A C BROWN; S BENAIM
Journal:  J Ment Sci       Date:  1961-05
  7 in total
  9 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 4.  Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Authors:  Daniel Weintraub; Knashawn H Morales; Paul J Moberg; Warren B Bilker; Catherine Balderston; John E Duda; Ira R Katz; Matthew B Stern
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

5.  Depression in Parkinson disease: a disabling but neglected factor.

Authors:  R Cantello; A Riccio; L Scarzella; D Leotta; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1984-12

Review 6.  Treatment of depression in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

7.  Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals.

Authors:  A Lupp; K I Bär; C H Lücking; T J Feuerstein
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Synergistic anticataleptic effect of imipramine and nicotine in a rotenone-induced rat model.

Authors:  Ilya D Ionov; Irina I Pushinskaya; Nicholas P Gorev; Larissa A Shpilevaya
Journal:  Psychopharmacology (Berl)       Date:  2019-05-08       Impact factor: 4.415

9.  Depression in Parkinson's disease: health risks, etiology, and treatment options.

Authors:  Pasquale G Frisina; Joan C Borod; Nancy S Foldi; Harriet R Tenenbaum
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.